Blood Pressure Medications During Chemotherapy
For patients undergoing chemotherapy who develop hypertension, ACE inhibitors or ARBs are the preferred first-line agents, with calcium channel blockers (specifically amlodipine) as an excellent alternative, particularly for chemotherapy-induced hypertension from VEGF inhibitors like bevacizumab. 1, 2
Preferred Antihypertensive Agents
First-Line Choices
ACE Inhibitors and ARBs are the most strongly recommended based on cardioprotective effects:
- These agents reduce mortality and improve cardiovascular outcomes in patients with breast cancer undergoing doxorubicin chemotherapy 3
- They preserve left ventricular ejection fraction during cardiotoxic chemotherapy 4
- ACE inhibitors specifically reduce arrhythmias (RR 0.17) in chemotherapy patients 4
- Particularly beneficial in patients with diabetes receiving chemotherapy 5
Calcium Channel Blockers (Amlodipine specifically):
- Amlodipine 5 mg daily is the recommended starting agent for bevacizumab-induced hypertension 2
- Equivalent cardiovascular outcomes to ACE inhibitors/ARBs in most patients 5
- Dihydropyridine CCBs are safe and effective during chemotherapy 1
- Avoid non-dihydropyridine CCBs (diltiazem, verapamil) due to drug interactions with chemotherapy agents 1
Second-Line and Combination Therapy
Beta-blockers:
- Provide modest cardioprotection and preserve ejection fraction (mean difference 2.77%) 4
- Reduce heart failure incidence (RR 0.29) and cardiotoxicity (RR 0.44) 4
- However, associated with worse outcomes compared to ACE inhibitors/ARBs in some studies 5
- Use cautiously; not first-line but acceptable in combination therapy
Thiazide/Thiazide-like Diuretics:
- Generally avoid as monotherapy - associated with increased risk of breast cancer recurrence (36% higher) and mortality (51% higher) in some populations 6
- May be used in combination therapy if needed for blood pressure control 7, 8
Treatment Algorithm for Chemotherapy Patients
For VEGF Inhibitor-Induced Hypertension (Bevacizumab, Sorafenib, Sunitinib):
Step 1: Start amlodipine 5 mg daily 2
- Reassess after 2 weeks
- Target: Clinic BP <160/100 mmHg or ambulatory BP <150/95 mmHg
Step 2: Add ACE inhibitor (e.g., perindopril 2 mg daily) OR ARB (e.g., losartan 50 mg daily) 2
Step 3: Add indapamide 2.5 mg daily if needed 2
Step 4: Consider increasing doses or adding low-dose spironolactone (if K+ <4.5 mmol/L) 2
For Anthracycline Chemotherapy (Doxorubicin):
Preferred: ACE inhibitor or ARB as first-line 5, 3
- These provide cardioprotection beyond blood pressure control
- Reduce risk of heart failure and death
Alternative: Calcium channel blocker if ACE inhibitor/ARB not tolerated 5
Blood Pressure Targets and Monitoring
Treatment Thresholds:
- Do not delay chemotherapy if clinic BP <160/100 mmHg 2
- Initiate antihypertensive therapy if BP ≥160/100 mmHg (clinic) or ≥150/95 mmHg (ambulatory/home monitoring) 2
Monitoring Schedule:
- Measure BP before each chemotherapy infusion 2
- Daily home BP monitoring during first cycle of VEGF inhibitor therapy 9
- Every 2-3 weeks once stable 9
When to Hold Chemotherapy:
- Clinic BP ≥180/110 mmHg - hold dose, treat urgently 2
- Hypertensive crisis or encephalopathy - permanently discontinue VEGF inhibitor 2
Critical Caveats
Drug Interactions: Non-dihydropyridine calcium channel blockers interact with many chemotherapy agents through CYP3A4 metabolism - avoid diltiazem and verapamil 1
Timing Matters: Hypertension from VEGF inhibitors typically occurs within hours to days of starting therapy and resolves after treatment completion (median 87 days post-treatment) 2
Shared Care: Coordinate between oncology and primary care for optimal blood pressure management, with clear communication about treatment goals 2
Pre-existing Hypertension: Patients already on antihypertensives should have treatment optimized before starting chemotherapy, following standard hypertension guidelines 7, 8